Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.
HIV
cardiovascular
gender identity
gender-affirming hormone treatment
transgender spectrum
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
09 07 2020
09 07 2020
Historique:
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
11
3
2021
Statut:
ppublish
Résumé
Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.
Identifiants
pubmed: 32645160
pii: 5869453
doi: 10.1093/infdis/jiaa213
pmc: PMC7347077
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
S31-S40Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK040561
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069456
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069463
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068636
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL123339
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069463
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106701
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL123336
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Soc Sci Med. 2019 Jun;230:280-294
pubmed: 31035207
Front Psychol. 2010 Nov 16;1:192
pubmed: 21833252
Lancet. 2016 Jul 23;388(10042):412-436
pubmed: 27323919
HIV AIDS (Auckl). 2019 Nov 07;11:275-285
pubmed: 31807083
AIDS Care. 2020 Mar;32(3):310-315
pubmed: 31530004
J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 3:S243-7
pubmed: 27429190
J Virus Erad. 2016 Apr 01;2(2):87-93
pubmed: 27482441
Am Heart J. 2019 Jun;212:23-35
pubmed: 30928825
AIDS. 2019 Mar 1;33(3):363-375
pubmed: 30703068
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):e158-e160
pubmed: 31021991
Open Forum Infect Dis. 2017 Feb 28;4(1):ofw047
pubmed: 28480227
J Interpers Violence. 2019 Sep 17;:886260519876024
pubmed: 31526070
AIDS Behav. 2019 Oct;23(10):2849-2858
pubmed: 31402416
Clin Infect Dis. 2019 Sep 29;:
pubmed: 31563942
Rev Endocr Metab Disord. 2018 Sep;19(3):243-251
pubmed: 30073551
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):181-8
pubmed: 26361171
Curr HIV/AIDS Rep. 2018 Apr;15(2):136-146
pubmed: 29504062
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e39-e41
pubmed: 29847481
J Womens Health (Larchmt). 2018 Sep;27(9):1162-1169
pubmed: 29608129
Eur J Endocrinol. 2013 Sep 13;169(4):471-8
pubmed: 23904280
Clin Infect Dis. 2020 Mar 3;70(6):1131-1138
pubmed: 31573601
J Assoc Nurses AIDS Care. 2018 May - Jun;29(3):371-382
pubmed: 29475784
Lancet Infect Dis. 2013 Mar;13(3):214-22
pubmed: 23260128
Am J Public Health. 2019 Jan;109(1):e1-e8
pubmed: 30496000
Ann Intern Med. 2017 Aug 15;167(4):256-267
pubmed: 28738421
J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 3:S207-9
pubmed: 27429184